Ma-Spore ALL 2020 Study

Summary

The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia (B-ALL) in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy.

Conditions

• B Lymphoblastic Leukemia

Interventions

DRUG

Prednisolone

Oral

DRUG

Dexamethasone

Oral

DRUG

Vincristine

Intravenous

DRUG

Methotrexate

Oral/ intrathecal/intravenous/subcutaneous

DRUG

L-Asparaginase

Intramuscular

DRUG

Pegylated asparaginase

Intravenous

DRUG

Erwinase

Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)

DRUG

Dasatinib

Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)

DRUG

Imatinib

Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)

DRUG

Cyclophosphamide

Intravenous

DRUG

Cytarabine

Subcutaneous/ Intravenous

DRUG

Mercaptopurine

Oral

DRUG

Thioguanine

Oral

DRUG

Rituximab

Intravenous

DRUG

Doxorubicin

Intravenous

DRUG

Fludarabine

Intravenous

Sponsors & Collaborators

• National University Hospital, Singapore

  lead OTHER

Principal Investigators

• Allen Eng Juh Yeoh, MBBS · Professor

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Max Age

40 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-03-04

Primary Completion

2030-03-31

Completion

2030-03-31

Countries

• Malaysia
• Singapore

Study Locations